Monoamine Dysfunction has been linked to both Affective Disorders and Schizophrenia. Drawing upon Relevant Evidence, Critically Evaluate the role of Monoamines in each of these Disorders. Assessment Number 2
Module Leader ' Dr Rebecca Jenks
Monoamine Dysfunction has been linked to both Affective Disorders and Schizophrenia. Drawing upon Relevant Evidence, Critically Evaluate the role of Monoamines in each of these Disorders.
Schizophrenia is a condition characterised by hallucinations, hearing voices and other dilutions which are known as the positive symptoms. Negative symptoms include social withdraw, flattened emotional response and an inability to experience pleasure. Prevalence is equally split between men and women; however there tends to be an earlier onset for men (20-28) than for women (26-32), Castle et al (1991). Lifetime occurrence is at around 0.55%, Goldner et al (2002) but variations have been found across culture, with urban areas often displaying higher incidence rates even when drugs use and other factors are accounted for, Van Os (2004).
Monoamine dysfunction has been given as a possible explanation of schizophrenia, with plenty of research for support. In particular the Dopamine Hypothesis, which suggests that raised levels of dopamine within the mesolimbic pathway is the cause, and has been noted in schizophrenic patients. Supporting this it was found that amphetamines which raise dopamine levels were found to exacerbate psychotic (positive) symptoms in schizophrenics, Laruelle (1996). In addition all of the early anti-psychotic drugs were chemicals that blocked the function of dopamine in some way, Tollefson and Sanger (1999). Also the ability of these drugs to block dopamine receptors positively correlates with clinical potency, Snyder et al (1978). Furthermore the path of the mesolimbic pathway means it travels firstly through the amygdala, where activation can lead to hallucinations, and secondly through the nucleus accumbens where random activation can lead to disorganised thoughts. Some support for this theory can be found from the effect of the drug PCP. Also known as ‘angel dust’ it causes both the positive and negative symptoms of schizophrenia; and one of its major effects is to increase levels of dopamine within the mesolimbic pathway.
However this hypothesis has been criticized for being overly simplistic with the effect of PCP being evidence against a pure Dopamine Hypothesis. Whilst PCP increases overall levels of dopamine it actually decreases levels in the frontal lobes leading to hypofrontality. In addition it blocks NMDA sensitive glutamatergic transmission; the evidence coming from post-mortem brains of diagnosed schizophrenics, Konradi & Heckers (2003), whilst another glutamate blocking drug (ketamine) has a similar result, Lahti et al (2002), suggesting the effect of other chemicals in the brain. Further evidence against this hypothesis is that newer anti-psychotic medication often called atypical antipsychotic drugs are as or more effective in dealing with the positive symptoms whilst being far more effective against the negative symptoms. These drugs tend to have a lower affinity for dopamine and have an antagonistic effect on serotonin, whilst some even act as dopamine agonists, Jones and Pilowsky (2002). Furthermore the reduction of glutamate function is linked to poor performance on tests requiring frontal lobe and hippocampel activation such as the Wisconsin Sorting Task, where schizophrenics often score poorly on. .
In addition to the glutamate hypothesis there are other theories that aren’t based aren’t monoamine dysfunction. Firstly it has been suggested that there is a genetic link which in part has been strongly supported by evidence. Adoption studies provide evidence for the link, Kety and Ingraham (2000), as do twin studies, Tsuang et al (1991). The genetic link is strengthened by Owen et al (2005), who suggested that several genes interact to cause...
References: Castle, D. Wesseley, S. Der, G. Murray, R. M. (1991). The incidence of operationally defined schizophrenia in Camberwell 1965-84. British Journal of Psychiatry. 159., 790-794.
Davies, G. Welham, J. Chant, D. Torrey, E.F. McGrath, J. (2003) A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. Schizophrenia Bulletin. 29., 3., 587-593.
Dein, S (2006). Religion, spirituality and depression: implications for research and treatment. Primary Care and Community Psychiatry. 11., 2., 67 ' 72.
Delgado, P.L. (2000). Depression: The case for a monoamine deficiency. Journal of Clinical Psychiatry. 61., 6., 7 ' 11
Heim. C. Newport, D.J. Mletzko, T. Miller, A.H. Nemeroff, C.B. (2008). The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology. 33.,6., 693 ' 710.
Johnstone, E.C. Crow, T.J. Frith, C.D. Husband, J. & Kreel, L. (1976) Cerebral ventricular size and cognitive impairment in chronic schizophrenia. The Lancet. 2., 7992., 924-926.
Jones, H.M. & Pilowsky, L.S. (2002) Dopamine and antipsychotic drug action revisited. British journal of psychiatry. 181., 271-275.
Kessler, R.C (1997). The effects of stressful life events on depression. Annual revue of Psychology. 48., 191 ' 214.
Kety, S.S. & Ingraham, L.J. (2000) Adoption studies of schizophrenia. American Journal of Medical Genetics - Seminars in Medical Genetics. 97., 1., 18-22.
Konradi, C. & Heckers, S. (2003) Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacology and Therapeutics. 97., 2., 153-79.
Lahti, A.C. Weiler, M.A. Tamara Michaelidis, B.A. Parwani, A. & Tamminga, C.A. (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacolgy. 25., 4., 455-467.
Mendlewicz, J., & Rainer, J.D. (1977). Adoption study supporting genetic transmission in manic depresssive illness. Nature, 268, 327-329.
Molina, V. Reig, S. Sanz, J. (2005) Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophrenia Research. 81., 1., 61-71.
Mueser, K.T. & McGurk, S.R. (2004) Schizophrenia. The lancet. 363., 9426., 2063-72.
Murray, R.M. Wright, P. Takei, N. & Rifkin, L. (1995) Maternal influenza, obstetric complications, and schizophrenia. American Journal of Psychiatry. 152., 12., 1714-1720.
Nutt, D.J. (2008). Relationship of neurotransmitters to the symptoms of major depressive disorder. Journal of Clinical Psychiatry. 69., 4 ' 7.
Owen, M.J. Craddock, N. O’Donovan, M.C. (2005) Schizophrenia: genes at last? Trends in genetics. 21., 9., 518-25.
Raphael, B. (2000). Unmet Need for Prevention. in Andrews G, Henderson S (eds). Unmet Need in Psychiatry: Problems, Resources, Responses. Cambridge University Press. 138 ' 39
Sadock, B.J & Sadock, V.A. (2002) Kaplan and Sadock 's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry (9th ed.). Lippincott Williams & Wilkins: NY
Shah, N. Eisner, T. Farrell, M. & Raeder, C. (1999). An overview of SSRIs for the treatment of depression. Journal of the Pharmacy Society of Wisconsin. 3., 33-46.
Snyder, S.H. Creese, I & Prosser, T. (1978) Dopamine receptor binding: specificity, localization and regulation by ions and guanyl nucleotides. Life Sciences. 23., 5., 495-499.
Tollefson, G.D. & Sanger, T.M. (1999) Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? Schizophrenia Research. 1., 35., 13-21.
Tsuang, M.T. Faraone, S.V. & Tsuang, D.W. (1991) Genetics of Mental Disorders: What practitioners and students need to know. Guildford Publications Inc: New York, NY.
Van Os, J (2004). Does the urban environment cause psychosis? British Journal of Psychiatry. 184., 4., 287-288.
Videbech, P. (1997). MRI findings in patients with affective disorder: a meta-analysis. Acta Psychiatrica Scandinavica. 96., 3., 157 ' 68.
Please join StudyMode to read the full document